FDA 批准 ARS Pharmaceuticals 的无针鼻喷雾剂 Neffy 用于过敏反应治疗。 FDA approves ARS Pharmaceuticals' needle-free nasal spray, Neffy, for anaphylaxis treatment.

美国食品和药物管理局批准ARS药业公司的鼻喷雾,neffy,作为首个无针应急治疗严重过敏反应,包括过敏反应,适用于体重至少30公斤的成人和儿童. The FDA approved ARS Pharmaceuticals' nasal spray, neffy, as the first needle-free emergency treatment for severe allergic reactions, including anaphylaxis, for adults and children weighing at least 30 kg. Neffy 可作为 EpiPen 和其他肾上腺素注射剂的替代品，有可能减少快速治疗过敏反应（一种危及生命的疾病）的障碍。 Neffy serves as an alternative to EpiPen and other epinephrine injections, potentially reducing barriers to rapid treatment of anaphylaxis, a life-threatening condition. 这标志着首次批准用于治疗过敏反应的鼻喷雾剂. This marks the first approval for a nasal spray for treating anaphylaxis.